Tango Therapeutics, Inc.
TNGX
株式のランク
#4497
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
株価
$27.18
最終同期: 2026-07-31
時価総額
$3.38B
変化（1日）
-1.41%
変化（1年）
213.86%
国
US
取引 Tango Therapeutics, Inc. (TNGX)
カテゴリー
Healthcare
Tango Therapeutics, Inc.（TNGX）の株価履歴
終値の最高値: $28.53 （2026-07-01）
終値の最安値: $10.21 （2020-09-01）
終値の最安値: $10.21 （2020-09-01）
Tango Therapeutics, Inc. の株価履歴（2020 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 94.33% |
| 2025 | 186.22% |
| 2024 | -66.61% |
| 2023 | 25.09% |
| 2022 | -28.88% |
| 2021 | -3.27% |
| 2020 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $533.52 | 25.11% |
US
|
|
| $183.54 | 583.58% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $887.97 | 9.06% |
NL
|
